LOS ANGELES, May 19, 2025/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company, announced positive topline results from its Phase 1b/2a diSArm trial. The study evaluated AP-SA02, an intravenous multi-phage therapeutic, for the treatment of Staphylococcus aureus bacteremia in the intent-to-treat population. The trial, a multicenter, randomized, double-blind, placebo-controlled study, assessed the safety, tolerability, and efficacy of AP-SA02 in addition to best available antibiotic therapy versus antibiotic therapy alone. No treatment-related serious adverse events were observed. Armata has developed a proprietary manufacturing process capable of producing over 10,000 full courses of phage therapy annually at its California facility. The company plans to move towards a pivotal trial to further evaluate AP-SA02.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.